The effect of natural health products and traditional medicines on the activity of human hepatic microsomal-mediated metabolism of oseltamivir.

PURPOSE Oseltamivir is a prodrug that requires metabolic activation but there is little information on whether natural health products interact to prevent the biotransformation by the carboxylesterase. METHODS HPLC-DAD-ESI-MSD and fluorometric assays were used to determine if 50-pooled mixed gender human liver microsomes can mediate the formation of the active carboxylate metabolite and then if this reaction is affected by natural health products. RESULTS Extracts from 6 traditional Cree botanicals, a commercially available Echinacea product, Goldenseal and a traditional Chinese medicine reduced the formation of the active drug. In addition to oseltamivir carboxylate we report the detection of two new metabolites which are derivatives of oseltamivir carboxylate, one of which is a metabonate formed as a result of methanol. CONCLUSIONS In vitro studies would suggest that there is the potential for some natural health products used by patients in response to pandemic A/H1N1 to reduce drug efficacy. Further studies are required to determine if these potential interactions could be clinically significant.

[1]  Yan Jiang,et al.  Age- and Sex-Related Expression and Activity of Carboxylesterase 1 and 2 in Mouse and Human Liver , 2009, Drug Metabolism and Disposition.

[2]  I. Tamai,et al.  Oseltamivir (Tamiflu) Is a Substrate of Peptide Transporter 1 , 2009, Drug Metabolism and Disposition.

[3]  Julie A. Johnson,et al.  Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril. , 2009, Biochemical pharmacology.

[4]  J. Markowitz,et al.  Activation of the Antiviral Prodrug Oseltamivir Is Impaired by Two Newly Identified Carboxylesterase 1 Variants , 2009, Drug Metabolism and Disposition.

[5]  Yu-Jui Yvonne Wan,et al.  Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. , 2009, Biochemical pharmacology.

[6]  Y. Izumi,et al.  Synaptic and behavioral interactions of oseltamivir (Tamiflu) with neurostimulants , 2008, Human & experimental toxicology.

[7]  Julie A. Johnson,et al.  Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. , 2008, American journal of human genetics.

[8]  H. Kusuhara,et al.  P-glycoprotein Restricts the Penetration of Oseltamivir Across the Blood-Brain Barrier , 2008, Drug Metabolism and Disposition.

[9]  T. Fujita,et al.  Oseltamivir (Tamiflu) Efflux Transport at the Blood-Brain Barrier via P-Glycoprotein , 2008, Drug Metabolism and Disposition.

[10]  F. Akhlaghi,et al.  Anti-Influenza Prodrug Oseltamivir Is Activated by Carboxylesterase Human Carboxylesterase 1, and the Activation Is Inhibited by Antiplatelet Agent Clopidogrel , 2006, Journal of Pharmacology and Experimental Therapeutics.

[11]  M. Prentki,et al.  Selected plant species from the Cree pharmacopoeia of northern Quebec possess anti-diabetic potential. , 2006, Canadian journal of physiology and pharmacology.

[12]  C. Leduc,et al.  Plants used by the Cree Nation of Eeyou Istchee (Quebec, Canada) for the treatment of diabetes: A novel approach in quantitative ethnobotany. , 2006, Journal of ethnopharmacology.

[13]  P. Ward,et al.  The Pharmacokinetics and Tolerability of the Oral Neuraminidase Inhibitor Oseltamivir (Ro 64–0796/GS4104) in Healthy Adult and Elderly Volunteers , 2000, Journal of clinical pharmacology.

[14]  W. Lew,et al.  Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[15]  P. Ward,et al.  Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802 , 1999, Clinical pharmacokinetics.